SAN CARLOS, Calif., May 13, 2026
BeOne Medicines announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (sonrotoclax) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have previously received at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. The approval marks a major milestone in hematologic oncology, making BEQALZI the first and only BCL2 inhibitor approved for mantle cell lymphoma in the United States and the first newly approved BCL2 inhibitor in the country in more than a decade. BeOne stated that sonrotoclax was specifically engineered as a next-generation BCL2 inhibitor with enhanced potency, selectivity, and a pharmacologic profile designed to potentially improve efficacy, tolerability, and treatment convenience compared with earlier therapies in the class. The approval further strengthens the company’s expanding oncology portfolio and positions BEQALZI as a foundational targeted therapy for patients facing limited treatment options after progression on BTK inhibitors.
Phase 1/2 Trial Data Demonstrated Strong Clinical Responses
The FDA approval was supported by efficacy and safety findings from the ongoing Phase 1/2 BGB-11417-201 study, which evaluated sonrotoclax monotherapy in patients with relapsed or refractory mantle cell lymphoma. Data presented at the 67th American Society of Hematology (ASH) Annual Meeting demonstrated a 52% overall response rate (ORR) and a 16% complete response rate, highlighting meaningful anti-cancer activity in a patient population with historically poor outcomes and few remaining therapeutic options. The study also reported a median duration of response of 15.8 months, while the median time to response was only 1.9 months, indicating rapid disease control in responding patients.
Importantly, the company noted that treatment with sonrotoclax was generally well tolerated, reinforcing the potential for improved safety and long-term usability compared with older therapies targeting the same pathway. Continued approval for the indication will depend on confirmation of clinical benefit in the ongoing CELESTIAL-RRMCL confirmatory trial, which is currently underway. Sonrotoclax previously received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA, reflecting both the unmet medical need in mantle cell lymphoma and the therapy’s potential clinical significance.
BEQALZI Expands Treatment Options in Aggressive Blood Cancer
Mantle cell lymphoma is a rare but highly aggressive subtype of non-Hodgkin lymphoma characterized by frequent relapse and poor long-term survival outcomes, particularly after resistance develops to BTK inhibitor therapies. Approximately 3,300 new cases are diagnosed annually in the United States, and treatment options become increasingly limited as the disease progresses. By targeting the BCL2 protein, sonrotoclax is designed to restore the natural cell death process known as apoptosis, enabling malignant B cells to be eliminated more effectively.
Advertisement
BeOne emphasized that BEQALZI was developed with a differentiated pharmacokinetic and pharmacodynamic profile, including high selectivity, a shorter half-life, and reduced drug accumulation, potentially improving patient tolerability while preserving potent anti-tumor activity. Industry experts believe the approval could significantly reshape treatment sequencing strategies for relapsed mantle cell lymphoma patients and further accelerate development of next-generation BCL2-targeted therapies across hematologic malignancies.
The approval also reflects growing momentum in precision oncology, where highly selective targeted medicines are increasingly replacing conventional chemotherapy approaches in blood cancers. Physicians and researchers continue to focus on therapies capable of overcoming resistance mechanisms while minimizing treatment-related toxicity, an area where sonrotoclax may offer competitive advantages.
BeOne Strengthens Global Hematology Oncology Pipeline
Beyond mantle cell lymphoma, BeOne Medicines is continuing to expand development of sonrotoclax across multiple hematologic cancers. The therapy is already approved in China for relapsed or refractory mantle cell lymphoma as well as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) following prior therapy including BTK inhibitors. Regulatory submissions are also currently under review by the European Medicines Agency and additional global regulatory authorities.
The company is further evaluating sonrotoclax in combination regimens involving therapies such as zanubrutinib, with additional clinical data expected at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Sonrotoclax has also received FDA Fast Track and Orphan Drug Designations in additional indications including Waldenström macroglobulinemia, multiple myeloma, acute myeloid leukemia, and myelodysplastic syndrome.
With more than 2,200 patients enrolled across the global sonrotoclax development program, BeOne Medicines is positioning itself as a major competitor in the rapidly evolving hematology oncology market while advancing next-generation targeted therapies aimed at improving outcomes for patients with difficult-to-treat blood cancers.
Source: BeOne Medicines press release
